Immuneering Corp. Announces Annual Meeting of Stockholders on June 12, 2024

TL;DR

<b>Immuneering Corporation will hold its Annual Meeting of Stockholders virtually on June 12, 2024, to elect directors and ratify auditors.</b>

AI Summary

Immuneering Corp (IMRX) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Annual Meeting of Stockholders to be held virtually on June 12, 2024, at 11:00 a.m. ET. Robert J. Carpenter and Benjamin J. Zeskind, Ph.D. nominated for election as Class III directors. RSM US LLP nominated for ratification as independent registered public accounting firm for fiscal year ending December 31, 2024. Record date for stockholders entitled to notice and voting is April 18, 2024. Meeting will be held via live webcast at www.virtualshareholdermeeting.com/IMRX2024.

Why It Matters

For investors and stakeholders tracking Immuneering Corp, this filing contains several important signals. Stockholders will vote on the election of two Class III directors, impacting the company's board composition and strategic direction. The ratification of RSM US LLP as the independent auditor is crucial for financial transparency and regulatory compliance.

Risk Assessment

Risk Level: low — Immuneering Corp shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks indicated.

Analyst Insight

Stockholders should review the director nominees and auditor ratification proposals before the June 12, 2024, Annual Meeting.

Key Numbers

• June 12, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• April 18, 2024 — Record Date (Stockholders of record on this date are entitled to vote)
• 2027 — Director Term End (Term for elected directors until the annual meeting in 2027)
• December 31, 2024 — Fiscal Year End (Fiscal year for which RSM US LLP is being ratified as auditor)

Key Players & Entities

• Immuneering Corp. (company) — Registrant
• Robert J. Carpenter (person) — Director nominee
• Benjamin J. Zeskind, Ph.D. (person) — Director nominee
• RSM US LLP (company) — Independent registered public accounting firm
• April 18, 2024 (date) — Record date for stockholders
• June 12, 2024 (date) — Annual Meeting date
• December 31, 2024 (date) — Fiscal year end
• 245 Main Street, Second Floor, Cambridge, MA 02142 (address) — Company business address

FAQ

Industry Context

Immuneering Corporation operates in the pharmaceutical preparations industry, focusing on developing therapies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

What Investors Should Do

1. Review the qualifications of director nominees Robert J. Carpenter and Benjamin J. Zeskind.
2. Evaluate the appointment of RSM US LLP as the independent registered public accounting firm.
3. Ensure voting rights are exercised by the record date of April 18, 2024.

Key Dates

• 2024-04-18: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.
• 2024-06-12: Annual Meeting of Stockholders — Date for election of directors and ratification of auditors.

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual Meeting of Stockholders, providing details on upcoming proposals.

Filing Documents

• imrx-2024proxystatementdef.htm (DEF 14A) — 484KB
• a1.jpg (GRAPHIC) — 7KB
• proxycardjpg_pagex1.jpg (GRAPHIC) — 413KB
• proxycardjpg_pagex2.jpg (GRAPHIC) — 234KB
• 0001790340-24-000044.txt (&nbsp;) — 1385KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 30 CERTAIN TRANSACTIONS WITH RELATED PERSONS 32 Policies and Procedures Regarding Transactions with Related Persons 32 Certain Related Person Transactions 32 STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS 33 HOUSEHOLDING OF PROXY MATERIALS 33 202 3 ANNUAL REPORT 34 TABLE OF CONTENTS Immuneering Corporation 245 Main Street Second Floor Cambridge, MA 02142 PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 12, 2024 This proxy statement (the "Proxy Statement") and our annual report for the fiscal year ended December 31, 2023 (the "Annual Report" and, together with the Proxy Statement, the "proxy materials") are being furnished by and on behalf of the Board of Directors (the "Board of Directors" or "Board") of Immuneering Corporation (the "Company", "Immuneering", "we," "us" or "our") in connection with our 2024 annual meeting of stockholders (the "Annual Meeting"). The proxy materials are first being sent on or about April 23, 2024 to all stockholders entitled to notice of and to vote at the Annual Meeting. The Annual Meeting will be a completely virtual meeting and will be held via live webcast in order to facilitate stockholder attendance and participation by enabling stockholders to participate and vote electronically from any location. Details regarding how to attend the meeting online are more fully described below. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON WEDNESDAY, JUNE 12, 2024. A Notice Regarding the Internet Availability of Proxy Materials (the "Notice") will be mailed to certain of our stockholders. The proxy materials can be accessed at our Investor Relations website at httpsir.immuneering.com or by following the instructions in the Notice. General information about the Annual Meeting and Voting How do I attend the Annual Meeting The Annual Meeting will be held on Wednesday, June

View Full Filing

View this DEF 14A filing on SEC EDGAR